| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAG2 mRNA | CTD | PMID:22079256 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BAG2 mRNA | CTD | PMID:20106945 |
| 17beta-estradiol | affects expression | ISO | RGD:1621366 | 6480464 | Estradiol affects the expression of BAG2 mRNA | CTD | PMID:15598610 |
| 4,4'-diaminodiphenylmethane | decreases expression | ISO | RGD:1621366 | 6480464 | 4,4'-diaminodiphenylmethane results in decreased expression of BAG2 mRNA | CTD | PMID:18648102 |
| 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid | increases expression | EXP | | 6480464 | Am 580 results in increased expression of BAG2 mRNA | CTD | PMID:16982809 |
| 5-aza-2'-deoxycytidine | decreases expression | EXP | | 6480464 | decitabine results in decreased expression of BAG2 mRNA | CTD | PMID:19363521 |
| 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | TP53 protein affects the reaction [decitabine results in decreased expression of BAG2 mRNA] | CTD | PMID:19363521 |
| aflatoxin B1 | decreases expression | ISO | RGD:1621366 | 6480464 | Aflatoxin B1 results in decreased expression of BAG2 mRNA | CTD | PMID:19770486 |
| all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of BAG2 mRNA | CTD | PMID:21934132 |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of BAG2 mRNA | CTD | PMID:22316170 |
| benzo[a]pyrene | increases expression | ISO | RGD:1621366 | 6480464 | Benzo(a)pyrene results in increased expression of BAG2 mRNA | CTD | PMID:22228805 |
| bisphenol A | increases expression | ISO | RGD:1621366 | 6480464 | bisphenol A results in increased expression of BAG2 protein | CTD | PMID:15215581 |
| coumestrol | increases expression | EXP | | 6480464 | Coumestrol results in increased expression of BAG2 mRNA | CTD | PMID:19167446 |
| coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA | CTD | PMID:19167446 |
| cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of BAG2 mRNA | CTD | PMID:20106945 |
| dibutyl phthalate | increases expression | ISO | RGD:1621366 | 6480464 | Dibutyl Phthalate results in increased expression of BAG2 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | increases expression | ISO | RGD:1585173 | 6480464 | Dibutyl Phthalate results in increased expression of BAG2 mRNA | CTD | PMID:21266533 |
| etoposide | affects response to substance | EXP | | 6480464 | BAG2 protein affects the susceptibility to Etoposide | CTD | PMID:16217747 |
| hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of BAG2 mRNA | CTD | PMID:20044591 |
| paracetamol | affects expression | ISO | RGD:1621366 | 6480464 | Acetaminophen affects the expression of BAG2 mRNA | CTD | PMID:17562736 |
| pirinixic acid | multiple interactions | ISO | RGD:1621366 | 6480464 | [pirinixic acid co-treated with PPARA] results in increased expression of BAG2 mRNA | CTD | PMID:20813756 |
| pirinixic acid | increases expression | ISO | RGD:1621366 | 6480464 | pirinixic acid results in increased expression of BAG2 mRNA | CTD | PMID:18301758 PMID:20813756 |
| pirinixic acid | increases expression | ISO | RGD:1621366 | 6480464 | pirinixic acid results in increased expression of BAG2 mRNA | CTD | PMID:20813756 PMID:18301758 |
| pirinixic acid | multiple interactions | ISO | RGD:1621366 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of BAG2 mRNA | CTD | PMID:19710929 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BAG2 mRNA | CTD | PMID:21632981 |
| resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA | CTD | PMID:19167446 |
| rosiglitazone | increases expression | EXP | | 6480464 | rosiglitazone results in increased expression of BAG2 mRNA | CTD | PMID:16982809 |
| tetrachloromethane | increases expression | ISO | RGD:1621366 | 6480464 | Carbon Tetrachloride results in increased expression of BAG2 mRNA | CTD | PMID:17484886 |
| trans-resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA | CTD | PMID:19167446 |
| trimellitic anhydride | increases expression | ISO | RGD:1621366 | 6480464 | trimellitic anhydride results in increased expression of BAG2 mRNA | CTD | PMID:19042947 |
| valproic acid | affects expression | ISO | RGD:1621366 | 6480464 | Valproic Acid affects the expression of BAG2 mRNA | CTD | PMID:17292431 |
| valproic acid | decreases expression | ISO | RGD:1621366 | 6480464 | Valproic Acid results in decreased expression of BAG2 mRNA | CTD | PMID:21427059 |
| vancomycin | decreases expression | ISO | RGD:1621366 | 6480464 | Vancomycin results in decreased expression of BAG2 mRNA | CTD | PMID:18930951 |
| zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of BAG2 mRNA | CTD | PMID:18593933 |
| zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of BAG2 mRNA | CTD | PMID:18593933 |